Background: RIMTCORE study showed (ERS Congress 2015) that IMT within a 3-week-PR leads to benefits concerning PI max and FIV1 but not with respect to QoL (SGRQ, CAT) and 6MWD. This secondary analysis aims to clarify if there are subgroups with clinical benefits. Methods: RCT, 602 COPD patients GOLD grade 2-4 (IG/GC n = 300/302), intention-to-treat-analysis. Results: Significant moderator effects for gender were found in CAT (p<0.001), CCQ (p=0.011) and SGRQ total (p=0.042). Results from selected simple effect analyses are shown in table 1. In women, the IG showed significantly higher effects in CAT. However, in men, the CG showed higher effects in CAT and SGRQ. Additionally significant interaction effects for “PR within 14 days after hospitalization due to AECOPD” versus “stable COPD” were found in SGRQ (p=0.041), where the CG showed higher effects than the IG. Furthermore, but only in the per-protocol-analysis, there was a significant benefit for women of the IG concerning 6MWD (adj. mean diff. + 13.4m).

Discussion: The still ongoing evaluation of the long-term results will show whether the slightly poorer results of the IG in men and in patients directly after AECOPD concerning QoL are only passing effects because of the strenuous IMT, or whether these are lasting subgroup differences. In the latter case, the indication for IMT within PR should be reconsidered for these subgroups.